Camlin Fine Sciences Ltd

- There is no explicit mention of any current or future fundraising through debt or equity in the transcript. - The company discussed expected CAPEX for repurposing plants (Rs 20-30 crore for China Heliotropin plant, Rs 2-3 million for Italy plant), but these costs are expected to be borne by partners or internally funded. - Finance costs have not increased due to additional borrowing; the increase is mainly due to foreign exchange impact. - No new mentions or plans of equity or debt fundraising were disclosed during the call.

- Repurposing of China Heliotropin plant with expected CAPEX of Rs 20-30 crores, to be borne by the partner (no cash outflow for Camlin Fine Sciences). Timeline not specified. - Italy plant repurposing with anticipated CAPEX of Rs 2-3 million, expected to take 6-9 months. Revenues post-repurposing to start next year with EBITDA margins of 10-12%. - Acquisition of Vitafor Invest NV, Belgium completed on June 11, 2024, enabling expansion into Northern Africa and East European markets with synergies in blends business. - No specific CAPEX mentioned related to the Vitafor acquisition, but integration and scaling up initiatives ongoing. - No other immediate CAPEX or strategic investment details disclosed in the call.

- Blends business is expected to sustain robust growth with a healthy and substantial topline increase. - Aroma segment's temporary weakness anticipated to be overcome in H2 with improved quality and quantity, especially in Vanillin products. - Overall consolidated revenue remained stable despite Q1 softness, with demand recovering in Latin and South American markets. - Pricing in Vanillin is seeing green shoots and some volume improvements are expected. - Anti-dumping actions in US and Europe against Chinese manufacturers expected to positively impact Vanillin sales. - The Vitafor acquisition opens new geographic markets and product avenues, anticipated to scale up over coming quarters. - Management targets achieving double-digit EBITDA margin and revenue growth around Rs. 2,000 crore for the year FY25. - Recovery in demand expected in next quarters, with cautious optimism about pricing stabilization and operational efficiencies improving margins.

- The company expects to stabilize performance, revenue, and margins amid improving economic cues. - Robust growth in the blends business is anticipated to sustain through the year. - Aroma segment weakness is expected to be overcome in the second half of FY25 with improved quality and quantity. - EBITDA margins are targeted to reach double digits for the full year FY25. - Topline growth is expected to be healthy and substantial, targeting around Rs. 2,000 crore revenue for the year. - Operational efficiencies and some positive pricing trends, especially in Vanillin, are expected to support margin improvement. - Repurposing of European and Italy facilities is underway, with new revenue streams expected next year, aiming at 10-12% EBITDA margins from these plants in the future. - Lockheed Martin related business is expected to potentially yield substantial numbers 2-3 years out, though current contributions and timelines are uncertain.

- Regarding the Lockheed Martin business, it is currently in the commissioning phase for their first commercial battery expected within this year. - Commercial scaling and launch timelines are uncertain; thus, exact order book details and near-term business outlook are not specified. - The company anticipates that significant revenue contributions from this business could materialize 2-3 years out once the battery is successfully commercialized. - No specific order book figures or pending orders were disclosed for Lockheed Martin or other segments in the call. - Hence, the current order book is not quantifiable at this time, and the company considers Lockheed Martin business still in the pipeline phase.